Search

Your search keyword '"J.P. Fermand"' showing total 7 results
Start Over Author "J.P. Fermand"
7 results on '"J.P. Fermand"'

2. PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?

Author

S. Sotton, Bernard Tardy, H. Thollot, P. Moreau, Fabien Tinquaut, Ismail Elalamy, X. Leleu, Emilie Chalayer, C. Hulin, J.P. Fermand, A. Teste, and Denis Guyotat

Subjects
medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, Newly diagnosed, business, medicine.disease, Venous thromboembolism, Multiple myeloma
Published
2021
Full Text
View/download PDF

3. Campylobacter infection in adult patients with primary antibody deficiency

Author

Jérémie Dion, Marion Malphettes, Lucie Bénéjat, Francis Mégraud, Alain Wargnier, David Boutboul, Lionel Galicier, Vincent Le Moing, Patrick Giraud, Arnaud Jaccard, Raphaële Nove-Josserand, Claire Fieschi, Eric Oksenhendler, Laurence Gérard, E. Oksenhendler, C. Fieschi, M. Malphettes, L. Galicier, S. Georgin, J.P. Fermand, J.F. Viallard, A. Jaccard, C. Hoarau, Y. Lebranchu, A. Bérezné, L. Mouthon, M. Karmochkine, N. Schleinitz, I. Durieu, R. Nove-Josserand, V. Chanet, V. Le-Moing, N. Just, C. Salanoubat, R. Jaussaud, F. Suarez, O. Hermine, P. Solal-Celigny, E. Hachulla, G. Condette-Wojtasik, L. Sanhes, M. Gardembas, I. Pellier, P. Tisserant, M. Pavic, B. Bonnotte, J. Haroche, Z. Amoura, L. Alric, M.F. Thiercelin, L. Tetu, D. Adoue, P. Bordigoni, T. Perpoint, P. Sève, P. Rohrlich, J.L. Pasquali, P. Soulas-Sprauel, L.J. Couderc, P. Giraud, A. Baruchel, I. Deleveau, F. Chaix, J. Donadieu, F. Tron, C. Larroche, A.P. Blanc, A. Masseau, M. Hamidou, G. Gorochov, J.L. Garnier, H. Moins, L. Gérard, Hôpital Saint-Louis, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7), Recherche clinique appliquée à l'hématologie ((EA_3518)), Université Paris Diderot - Paris 7 (UPD7), Université de Bordeaux (UB), Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Recherche clinique appliquée à l'hématologie (URP_3518), Université de Paris (UP), Clinique Pont-de-Chaume, CHU Limoges, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), DEFI study group: E Oksenhendler, C Fieschi, M Malphettes, L Galicier, S Georgin, J P Fermand, J F Viallard, A Jaccard, C Hoarau, Y Lebranchu, A Bérezné, L Mouthon, M Karmochkine, N Schleinitz, I Durieu, R Nove-Josserand, V Chanet, V Le-Moing, N Just, C Salanoubat, R Jaussaud, F Suarez, O Hermine, P Solal-Celigny, E Hachulla, G Condette-Wojtasik, L Sanhes, M Gardembas, I Pellier, P Tisserant, M Pavic, B Bonnotte, J Haroche, Z Amoura, L Alric, M F Thiercelin, L Tetu, D Adoue, P Bordigoni, T Perpoint, P Sève, P Rohrlich, J L Pasquali, P Soulas-Sprauel, L J Couderc, P Giraud, A Baruchel, I Deleveau, F Chaix, J Donadieu, F Tron, C Larroche, A P Blanc, A Masseau, M Hamidou, G Gorochov, J L Garnier, H Moins, C Fieschi, M Malphettes, L Gérard, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), and Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)

Subjects
Adult, Male, medicine.medical_specialty, Gastrointestinal Diseases, [SDV]Life Sciences [q-bio], Primary Immunodeficiency Diseases, Population, medicine.disease_cause, Antibodies, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Internal medicine, Campylobacter Infections, medicine, Prevalence, Immunology and Allergy, Humans, 030212 general & internal medicine, education, ComputingMilieux_MISCELLANEOUS, education.field_of_study, Univariate analysis, business.industry, Campylobacter, Liver Diseases, Middle Aged, medicine.disease, Comorbidity, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, 3. Good health, Diarrhea, 030228 respiratory system, Bacteremia, Coinfection, Female, France, medicine.symptom, business, Complication, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; Primary antibody deficiency (PAD) is characterized by a defective immunoglobulin production and recurrent infections, mostly involving respiratory and gastrointestinal tracts. Chronic or recurrent diarrhea is reported in up to 23%. Campylobacter infection is a common cause of infectious diarrhea, reported in 1.2% to 7.5% of patients with common variable immunodefi-ciency (CVID), the most frequent PAD. The aim of this study was to describe Campylobacter infection in patients with PAD included in a large nationwide study and analyze factors associ-ated with susceptibility to this pathogen. The DEFI (DEFicit Immunitaire) study is an ongoing large cross-sectional French multicentric study of adults with PAD, with retrospective collection of clinical data. All patients with a history of bacteriologically documented Campylobacter infection were identified, and clinical data were collected for each episode. Factors associated with recurrent infection were assessed as oddsratio (OR) and 95% confidence interval (CI), calculated by means of simple regression analysis. In patients with available material, strains of each episode were characterized using molecular analysis and compared (Table E1, available in this article’s Online Repository at www.jaci-inpractice.org). A com-parison of immunodeficiency-related characteristics of patients with and without Campylobacter infection was performed in the homogeneous group of patients with CVID. The control group included patients with CVID from DEFI centers who confirmed that patients did not develop Campylobacter infection after enrollment (Figure E1, available in this article’s Online Repository at www.jaci-inpractice.org). After correction for multiple comparisons, P

Published
2018
Full Text
View/download PDF

4. Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency

Author

Rémi Bertinchamp, Laurence Gérard, David Boutboul, Marion Malphettes, Claire Fieschi, Eric Oksenhendler, E. Oksenhendler, C. Fieschi, M. Malphettes, L. Galicier, D. Boutboul, J.P. Fermand, J.F. Viallard, A. Jaccard, C. Hoarau, Y. Lebranchu, A. Bérezné, L. Mouthon, M. Karmochkine, N. Schleinitz, I. Durieu, R. Nove-Josserand, V. Chanet, V. Le-Moing, N. Just, C. Salanoubat, R. Jaussaud, F. Suarez, O. Hermine, P. Solal-Celigny, E. Hachulla, L. Sanhes, M. Gardembas, I. Pellier, P. Tisserant, M. Pavic, B. Bonnotte, J. Haroche, Z. Amoura, L. Alric, M.F. Thiercelin, L. Tetu, D. Adoue, P. Bordigoni, T. Perpoint, P. Sève, P. Rohrlich, J.L. Pasquali, A.S. Korganow, P. Soulas, L.J. Couderc, E. Catherinot, P. Giraud, A. Baruchel, I. Deleveau, F. Chaix, J. Donadieu, F. Tron, C. Larroche, A.P. Blanc, A. Masseau, M. Hamidou, G. Kanny, M. Morisset, F. Millot, O. Fain, R. Borie, A. Perlat, B. Bienvenue, B. Autran, G. Gorochov, J.L. Garnier, H. Moins, G. Maki, L. Gérard, Service d'Immunopathologie [Hôpital Saint-Louis, Paris], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Recherche clinique appliquée à l'hématologie ((EA_3518)), Université Paris Diderot - Paris 7 (UPD7), Différenciation et progression tumorale des lymphocytes, École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-CHU Saint Louis [APHP], and École pratique des hautes études (EPHE)-Institut Universitaire d'Hématologie (IUH)

Subjects
0301 basic medicine, Adult, CD4-Positive T-Lymphocytes, Male, Pediatrics, medicine.medical_specialty, Opportunistic infection, T cell, Hypogammaglobulinemia, Population, Late onset combined immunodeficiency, Opportunistic Infections, 03 medical and health sciences, Agammaglobulinemia, Overall survival, Immunology and Allergy, Medicine, Immunodeficiency, Humans, [SDV.IMM.ALL]Life Sciences [q-bio]/Immunology/Allergology, education, education.field_of_study, business.industry, Common variable immunodeficiency, CVID, Definition, Middle Aged, medicine.disease, Prognosis, Confidence interval, 3. Good health, Surgery, CD4 Lymphocyte Count, 030104 developmental biology, medicine.anatomical_structure, Common Variable Immunodeficiency, Female, business
Abstract

International audience; BACKGROUND:In 2014, the European Society for Immune Deficiencies (ESID) revised the common variable immunodeficiency (CVID) diagnosis criteria by incorporating new clinical and biological markers. The new definition appeared more restrictive but had not yet been evaluated in a large cohort of patients.OBJECTIVE:The objective of this study was to evaluate the impact of this new definition in a large cohort of patients with primary hypogammaglobulinemia.METHODS:Evaluation of 3 different CVID definitions (ESID/Pan-American Group for Immunodeficiency [PAGID] 1999, ESID 2014, DEFI 2015) in 521 patients included in the French DEFI study with a diagnosis of primary hypogammaglobulinemia.RESULTS:Using the ESID/PAGID 1999 definition, 351 patients were classified as CVID. The new ESID 2014 definition excluded 62 (18%) patients. Most of them (n = 56; 90%) had a less severe disease, whereas 6 (10%) presented with a severe disease with major T-cell defect. We propose different criteria (occurrence of opportunistic infection or very low naive CD4+ T-cell count) to define this population with severe T-cell defect. Sixty-two patients fulfilled these criteria, represented 20% of the initial CVID population but accounted for 77% of the deaths, with a 5-year overall survival of 67.6% (95% confidence interval, 51.0-79.6), and were considered as late onset combined immunodeficiency (LOCID).CONCLUSIONS:The new ESID definition for CVID still fails to exclude a large number of patients with severe T-cell defect. We propose a new definition (DEFI 2015) that excluded more patients with a T-cell defect and consider these patients as LOCID. This population has a poor outcome and should be considered as a distinct group requiring specific care.

Published
2016
Full Text
View/download PDF

5. Galectin-1 and Semaphorin-3A are two soluble factors conferring T cell immunosuppression to bone marrow mesenchymal stem cell

Author

Lepelletier, Y., Lecourt, S., Arnulf, B., Vanneaux, V., J.P., Fermand, Menasche, P., Domet, T., J.P., Marolleau, Hermine, O., Larghero, J., Cytokines, hématopoïèse et réponse immune (CHRI), Université Paris Descartes - Paris 5 (UPD5) - Institut National de la Santé et de la Recherche Médicale (INSERM) - Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Slama, Catherine

Subjects
ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2010

6. Autologus stern celle transplantation (ASCT) versus oral melphalan and high-dose dexamethasone in patients with AL (primary) amyloisdosis : results of the French multicentric randomized trial (MAG and IFM intergroup)

Author

Jaccard, Arnaud, Moreau, P., Leblond, V., Leleu, X., Bennoubker, L, Hermine, O., Recher, C., Malphette, M, Lioure, B., Royer, B, Grosbois, B., Jaubert, J., Preux, Pierre-Marie, Cogné, Michel, J.P., Fermand, Grelier, Elisabeth, Contrôle de la Réponse Immune B et des Lymphoproliférations (CRIBL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie clinique et thérapie cellulaire [CHU Limoges], CHU Limoges, Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), Laboratoire de Biostatistique et d'Informatique Médicale, and Université de Limoges (UNILIM)

Subjects
[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results